All Updates

All Updates

icon
Filter
Partnerships
GenKOre partners with Revvity to develop gene therapy treatments
Human Gene Editing
Jun 18, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Human Gene Editing

Human Gene Editing

Jun 18, 2024

GenKOre partners with Revvity to develop gene therapy treatments

Partnerships

  • CRISPR-based gene-editing company GenKOre has partnered with diagnostic and life sciences company Revvity's Gene Delivery franchise to develop gene therapy treatments for ocular disorders such as Leber congenital amaurosis 10 (LCA10) and Usher syndrome type 2A (USH2A).

  • Under the collaboration, GenKOre will use its proprietary TaRGET (tiny nuclease, augment RNA-based genome-editing technology) gene-editing platform combined with Revvity's adeno-associated virus (AAV) vector development technology to develop in vivo gene-editing therapies. The collaboration also aims to validate TaRGET's applicability for in vivo therapy, expand its utility for rare diseases, and address unmet medical needs through genomic medicine. 

  • GenKOre is a biotechnology company based in South Korea that specializes in gene-editing therapies. Its core technology, the TaRGET platform, includes various tools such as TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI for gene activation and inhibition, and TaRGET-FREE for gene knock-in applications. This platform consists of hypercompact CRISPR-Cas tools, which can be delivered via a single AAV vector, unlike the CRISPR-Cas9 system.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.